Isoray (NYSEAMERICAN:ISR) issued its quarterly earnings data on Monday. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.01), MarketWatch Earnings reports. Isoray had a negative return on equity of 15.33% and a negative net margin of 36.52%. During the same period in the prior year, the company earned ($0.02) EPS.
Shares of NYSEAMERICAN:ISR opened at $0.65 on Wednesday. The firm has a market capitalization of $91.95 million, a price-to-earnings ratio of -13.00 and a beta of 1.02. The stock’s 50-day moving average price is $0.45. Isoray has a 12 month low of $0.35 and a 12 month high of $2.81.
ISR has been the subject of several analyst reports. Zacks Investment Research upgraded Isoray from a “sell” rating to a “hold” rating in a research note on Thursday, July 15th. Northland Securities initiated coverage on Isoray in a research note on Tuesday, September 14th. They issued an “outperform” rating and a $1.25 target price for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $1.67.
IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.